METHYLENE BLUE FOR TREATMENT OF HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL, PHASE 2 https://doi.org/10.24875/RIC.21000028 NCT04370288- In the MB group, a significant improvement in SpO2 and RR was observed on the 3(rd) day (for both, p < 0.0001)… Continue reading "(22 May 2021) Methylene Blue- significantly improved SpO2 and respiratory distress"
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial https://www.medrxiv.org/content/10.1101/2021.05.19.21257429v1 NCT04530422- Two hundred and fifty patients were divided equally into each group. Both groups were similar regarding gender, but age was higher… Continue reading "(21 May 2021) Sofosbuvir- effective in treating patients with moderate COVID-19 infection"
Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial https://doi.org/10.1038/s41392-021-00603-6 NCT04369586, NCT04275245- In phase 1 study, 59 subjects were enrolled and assigned to eight cohorts, and no serious… Continue reading "(19 May 2021) Meplazumab- could accelerate the recovery of patients with a favorable safety profile"
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial https://www.medrxiv.org/content/10.1101/2021.05.18.21257267v1 NCT04381936-Between 27 November 2020 and 4 March 2021, 5610 patients were randomly allocated to receive colchicine and 5730 patients to receive usual care alone.… Continue reading "(18 May 2021) Colchicine- not associated with reductions in 28-day mortality"
Bamlanivimab Use in a Military Treatment Facility https://doi.org/10.1093/milmed/usab188 Of the COVID-19 patients who were given the option of a bamlanivimab infusion, 40 accepted and 6 did not (40/46, 86.9%). Thirty-six of 40 patients in the treatment group were contacted within… Continue reading "(17 May 2021) Bamlanivimab- 94.4 % showed improvement in 24-72 hrs"
Pre-Exposure Prophylaxis with Various Doses of Hdroxychloroquine among high-risk COVID 19 Healthcare Personnel: CHEER randomized controlled trial https://www.medrxiv.org/content/10.1101/2021.05.17.21257012v1 NCT04359537- Overall, 146 of 200 participants reported exposure to a confirmed COVID-19 case in the first month, 189 in the 2nd month… Continue reading "(17 May 2021) Hydroxychloroquine- PrEP HCQ does not significantly prevent illness compatible with COVID-19"
Hydroxychloroquine For Prophylaxis Of COVID-19 In Health Workers: A Randomized Clinical Trial https://www.medrxiv.org/content/10.1101/2021.05.14.21257059v1 NCT04318015- 127 subjects with a confirmed baseline negative RT-PCR SARS-CoV2 test were included in the trial, 62 assigned to HCQ and 65 to placebo. One subject (1.6%)… Continue reading "(16 May 2021) Hydroxychloroquine- number of symptomatic infections in health personnel were lower but not statistically significant"
Interferon-alpha-2b Aerosol Inhalation is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease-2019 https://doi.org/10.1111/bcp.14898 A total of 1401 patients were enrolled, 852 (60.8%) patients received 5,000,000 U of IFN-alpha-2b via aerosol inhalation twice daily. The primary outcome was a… Continue reading "(14 May 2021) Interferon alpha 2b- associated with improved clinical outcomes in patients"
Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial https://doi.org/10.1177/03000605211013550 NCT04523831-This was a randomized, blinded, placebo-controlled trial in patients with mild-to-moderate COVID-19 symptoms randomly assigned to treatment (n = 200) and placebo (n = 200) groups. The… Continue reading "(14 May 2021) Ivermectin, Doxycycline- number of patients with a </=7-day recovery was 61% Vs 44% in placebo"
A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19 https://www.medrxiv.org/content/10.1101/2021.05.13.21256973v1 NCT04315298- Four-hundred fifty-seven (457) and 1365 patients were randomized and treated in phases 2 and 3, respectively. Among phase 3 critical patients receiving MV (n=289; 34.3% on corticosteroids),… Continue reading "(14 May 2021) Sarilumab- No significant effect observed compared to corticosteroids"
